

Biagio Ricciuti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2706625/biagio-ricciuti-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122
papers

2,591
citations

29
h-index

47
g-index

157
ext. papers

3,783
ext. citations

3.8
avg, IF

5.27
L-index

#	Paper	IF	Citations
122	Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities.. <i>Tumori</i> , 2022 , 3008916211069412	1.7	
121	Association between immune-related adverse event timing and treatment outcomes.. <i>Onc Immunology</i> , 2022 , 11, 2017162	7.2	2
120	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	14
119	Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer 2021 , 9,		5
118	Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials. <i>Scientific Reports</i> , 2021 , 11, 6637	4.9	3
117	Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2021 , 81, 2566-2573	10.1	15
116	Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC) 2021 , 9,		15
115	Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in -activating mutant lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021 , 10, 1857-1872	4.4	10
114	DNMT3A mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9113-9113	2.2	1
113	Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9088-9088	2.2	2
112	Clinicopathologic and genomic correlates of tumor-infiltrating immune cells and immunotherapy efficacy in NSCLC.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9121-9121	2.2	1
111	Clinicopathologic, genomic, and tumor microenvironment correlates of aneuploidy and immunotherapy outcomes in NSCLC.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9119-9119	2.2	
110	Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9018-9018	2.2	1
109	Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC.. <i>JCO Precision Oncology</i> , 2021 , 5, 726-732	3.6	2
108	Changes in PD-L1 tumor proportion score are associated with CD274 gene (encoding PD-L1) copy number variation in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9029-9029	2.2	
107	Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	12
106	Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy. <i>Genes</i> , 2021 , 12,	4.2	1

105	Antibody-drug conjugates for lung cancer in the era of personalized oncology. <i>Seminars in Cancer Biology</i> , 2021 , 69, 268-278	12.7	8
104	SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1176-1187	8.9	6
103	Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. <i>Annals of Oncology</i> , 2021 , 32, 1391-1399	10.3	9
102	Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	5
101	What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?. <i>Cancer Journal (Sudbury, Mass)</i> , 2020 , 26, 485-495	2.2	3
100	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4135-4142	12.9	41
99	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 . <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2209-2221	7.4	32
98	Clinicopathological and genomic correlates of programmed cell death ligand-1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. <i>Annals of Oncology</i> , 2020 , 31, 807-814	10.3	34
97	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020 , 21, 498-508.e2	4.9	27
96	Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. <i>Future Oncology</i> , 2020 , 16, 1751-1766	3.6	10
95	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 1177-1187	7.4	38
94	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020 , 120, 17-24	7.5	41
93	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2020 , 26, 2615-2625	12.9	60
92	Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥ 50 . <i>Annals of Oncology</i> , 2020 , 31, 404-411	10.3	41
91	Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. <i>Lung Cancer</i> , 2020 , 145, 181-185	5.9	18
90	Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib. <i>Clinical Lung Cancer</i> , 2020 , 21, e478-e487	4.9	1
89	Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3518-3518	2.2	0
88	Clinical characteristics, genomic features, and recurrence risk of early-stage MET exon 14 mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9042-9042	2.2	1

87	Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9549-9549	2.2	3
86	Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9577-9577	2.2	1
85	Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15113-e15113	2.2	5
84	Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With Exon 14-Mutant NSCLC. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100072	1.4	1
83	Reply to Cortellini A. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100095	1.4	
82	Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9568-9568	2.2	
81	Influence of antibiotic therapy (ATB) on oncological outcomes of metastatic non-small cell lung cancer (mNSCLC) patients treated with chemo-immunotherapy (CIT).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3080-3080	2.2	
80	Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD). <i>Translational Lung Cancer Research</i> , 2020 , 9, 2428-2439	4.4	5
79	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort 2020 , 69, 1177		1
78	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020 , 134, 19-28	7.5	21
77	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100074	1.4	4
76	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. <i>Lung Cancer</i> , 2020 , 140, 59-64	5.9	22
75	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020 , 38, 576-583	2.2	71
74	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥50%: a multicenter study with external validation 2020 , 8,		29
73	Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC 2020 , 8,		24
72	Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. <i>European Journal of Radiology</i> , 2020 , 132, 109275	4.7	7
71	Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status 2020 , 8,		15
70	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020 , 6, 1952-1956	13.4	79

69	Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes. <i>Clinical and Translational Oncology</i> , 2020 , 22, 844-851	3.6	13
68	ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). <i>Clinical Lung Cancer</i> , 2020 , 21, 15-20	4.9	34
67	Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2020 , 22, 708-716	3.6	4
66	Antitumor activity of larotrectinib in tumors harboring gene fusions: a short review on the current evidence. <i>OncoTargets and Therapy</i> , 2019 , 12, 3171-3179	4.4	26
65	Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1927-1934	2.2	135
64	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2738-2745	2.2	82
63	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. <i>Oncologist</i> , 2019 , 24, e327-e337	5.7	80
62	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 2019 , 7, 57		155
61	Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer 2019 , 7, 87		43
60	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. <i>Clinical Lung Cancer</i> , 2019 , 20, 237-247.e1	4.9	76
59	Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. <i>Clinical Lung Cancer</i> , 2019 , 20, 178-185.e2	4.9	23
58	Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. <i>Annals of Oncology</i> , 2019 , 30, 1653-1659	10.3	110
57	Reply to J. Delyon et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3564-3565	2.2	
56	Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2577-2577	2.2	2
55	DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9077-9077	2.2	2
54	Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9082-9082	2.2	1
53	Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥0%.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9111-9111	2.2	2
52	Immune pneumonitis-related treatment discontinuations and outcomes in metastatic non-small cell lung cancer treated with nivolumab: A pooled analysis from a multi-institutional international collaboration.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 118-118	2.2	1

51	A comparison of mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients. <i>Translational Lung Cancer Research</i> , 2019 , 8, 135-143	4.4	10
50	Immune gene expression and bayesian network analysis in advanced non small cell lung cancer (NSCLC) patients treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20693-e20693	2.2	
49	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	27
48	Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). <i>Translational Lung Cancer Research</i> , 2019 , 8, 1163-1173	4.4	9
47	MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, S294-S295	8.9	3
46	MA09.11 Mechanisms of Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, S285	8.9	3
45	775 Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2019 , 114, S450-S451	0.7	1
44	High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art. <i>Trends in Endocrinology and Metabolism</i> , 2019 , 30, 12-24	8.8	29
43	Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. <i>Pharmacology & Therapeutics</i> , 2019 , 196, 105-116	13.9	56
42	Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 479-485	4.9	174
41	Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy. <i>Seminars in Cancer Biology</i> , 2019 , 56, 87-99	12.7	22
40	Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. <i>Medical Oncology</i> , 2018 , 35, 72	3.7	19
39	Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. <i>Lung Cancer</i> , 2018 , 120, 70-74	5.9	4
38	Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e9-e12	8.9	7
37	Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy. <i>Pharmacology & Therapeutics</i> , 2018 , 181, 156-168	13.9	77
36	Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e145-e147	8.9	12
35	Osimertinib. <i>Recent Results in Cancer Research</i> , 2018 , 211, 257-276	1.5	14
34	High density lipoprotein cholesterol and cancer: Marker or causative?. <i>Progress in Lipid Research</i> , 2018 , 71, 54-69	14.3	44

33	Immune-related adverse events to predict survival in patients with advanced non-small cell lung cancer treated with nivolumab: A multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9084-9084 ^{2.2}	2.2	2
32	Systemic effect of radiotherapy (RT) followed by programmed death 1 (PD-1) inhibitors in non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 177-177	2.2	
31	Updated outcomes of previously irradiated non-small-cell lung cancer (NSCLC) patients (pts) receiving programmed death 1 (PD-1) inhibitors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15158-e15158 ^{2.2}	2.2	
30	Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter?. <i>Thrombosis Research</i> , 2018 , 163, 51-53	8.2	10
29	Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018 , 12, 1753466618808659	4.9	13
28	mutation and DNA repair and synthesis genes in non-small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2018 , 9, 689-696	1.6	4
27	Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e220-e222	8.9	2
26	Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. <i>Medical Oncology</i> , 2017 , 34, 105	3.7	34
25	Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e51-e55	8.9	2
24	The safety of nivolumab for the treatment of advanced non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 101-109	4.1	6
23	Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 387-404	5.4	22
22	Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 1304-1311 ^{6.4} ¹⁷	6.4	17
21	Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand?. <i>Journal of Radiation Oncology</i> , 2017 , 6, 11-19	0.7	1
20	Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications. <i>Medical Oncology</i> , 2017 , 35, 4	3.7	16
19	Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?. <i>ESMO Open</i> , 2016 , 1, e000022	6	13
18	Alectinib activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. <i>Journal of Neuro-Oncology</i> , 2016 , 129, 355-61	4.8	18
17	Targeting EGFR and ALK in NSCLC: current evidence and future perspective. <i>Lung Cancer Management</i> , 2016 , 5, 79-90	2.6	1
16	Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy. <i>Medical Oncology</i> , 2016 , 33, 18	3.7	107

15	Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. <i>Expert Review of Respiratory Medicine</i> , 2016 , 10, 53-68	3.8	39
14	Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient. <i>Journal of Breast Cancer</i> , 2016 , 19, 324-329	3	10
13	Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland. <i>Tumori</i> , 2016 , 102,	1.7	4
12	Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. <i>Lung Cancer</i> , 2016 , 95, 82-7	5.9	15
11	Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer. <i>Clinical Drug Investigation</i> , 2016 , 36, 683-6	3.2	27
10	Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2601-13	4	17
9	Clinical outcome of platinum/etoposide treated large cell neuroendocrine carcinomas of the lung according to the type of radiotherapy received: a single institution analysis. <i>Annals of Oncology</i> , 2015 , 26, vi78	10.3	3
8	Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report. <i>Ecancermedicalscience</i> , 2015 , 9, 559	2.7	9
7	miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond traditional mechanisms of resistance. <i>Ecancermedicalscience</i> , 2015 , 9, 569	2.7	11
6	Melanosis coli or ischaemic colitis? That is the question. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	2
5	Future options for ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2015 , 87, 211-9	5.9	44
4	Double aortic arch with right positioned descending thoracic aorta and coexistent aortic kinking. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	1
3	Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. <i>Clinical Lung Cancer</i> , 2014 , 15, 86-92	4.9	34
2	Non-coding RNAs in lung cancer. <i>Oncoscience</i> , 2014 , 1, 674-705	0.8	30
1	Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of ≥50%		1